Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Lisa M, Arellano, Martha, Holloway, Stacie, Shepard, Marian, McMillan, Stephanie, Khoury, Hanna Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262317/
https://www.ncbi.nlm.nih.gov/pubmed/22282699
http://dx.doi.org/10.2147/JBM.S7158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262317/
https://www.ncbi.nlm.nih.gov/pubmed/22282699
http://dx.doi.org/10.2147/JBM.S7158

Ejemplares similares